Cefepime monotherapy for treatment of febrile neutropenia in children

Journal of Paediatrics and Child Health

Volumn 42, Issue 12, 2006, Pages 781-784

  Ariffin, Hany ^a   Ai, Chong Lee ^a   Lee, Chan Lee ^a   Abdullah, Wan Ariffin ^a  

^a UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

Cefepime; Childhood cancer; Febrile nutropenia; Montherapy

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CILASTATIN PLUS IMIPENEM; VANCOMYCIN;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFANT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEPHROTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; FEMALE; FEVER; HUMANS; INFANT; MALAYSIA; MALE; NEOPLASMS; NEUTROPENIA; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VANCOMYCIN;

EID: 33750625355     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2006.00977.x     Document Type: Article

References (20)

1. EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N. Engl. J. Med. 1987; 317: 1692-8.
2. Hughes WT, Armstrong D, Bodey GP et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin. Infect. Dis. 1997; 25: 551-73.
3. Ramphal R. Is monotherapy for febrile neutropenia still a viable alternative? Clin. Infect. Dis. 1999; 29: 508-14.
4. Kalman D, Barriere SL, Johnson BL. Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime and cefoperazone in serum and blister fluid. Antimicrob. Agents Chemother. 1992; 36: 453-7.
5. Tamura K, Imajo K, Akiyama N et al. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. Clin. Infect. Dis. 2004; 39 (Suppl. 1): S15-24.
6. Sanz MA, Lopez J, Lahuerta JJ et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J. Antimicrob. Chemother. 2002; 50: 79-88.
7. Chastagner P, Plouvier E, Eyer D, Plesiat P, Lozniewski A, Sommelet D. Efficacy of cefepime and amikacin in the empiric treatment of febrile neutropenic children with cancer. Med. Pediatr. Oncol. 2000; 34: 306-8.
8. Mustafa MM, Carlson L, Tkaczewski I, McCracken GH Jr, Buchanan GR. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatr. Infect. Dis. J. 2001; 20: 362-9.
9. Corapcioglu F, Sarper N. Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost. Pediatr. Hematol. Oncol. 2005; 22: 59-70.
10. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests. Document M2-A4, 4th edn. Villanova, PA: National Committee for Clinical Standards, 1990.
11. Murray PR, ed. Manual of Clinical Microbiology, 6th edn. Washington, DC: American Society of Microbiology Press, 1995.
12. Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young LS. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration. Clin. Infect. Dis. 1992; 15 (Suppl. 1): S206-15.
13. Ariffin H, Arasu A, Mahfuzah M et al. Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer. J. Paediatr. Child Health 2001; 37: 38-43.
14. Ariffin H, Navaratnam P, Lin HP. Surveillance study of bacteremic episodes in febrile neutropenic children. Int. J. Clin. Pract. 2002; 56: 237-40.
15. Ariffin H, Navaratnam P, Tan KK, Balan G. Antibiotic resistance patterns in nosocomial gram-negative bacterial infections in units with heavy antibiotic usage. J. Trop. Pediatr. 2004; 50: 26-31.
16. Queenan AM, Foleno B, Gownley C, Wira E, Bush K. Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J. Clin. Microbiol. 2004; 42: 269-75.
17. Kebudi R, Gorgun O, Ayan I, Gurler N, Akici F, Toreci K. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumours. Med. Pediatr. Oncol. 2001; 36: 434-41.
18. Mustafa MM, Carlson L, Tkaczewski I, McCracken GH, Buchanan GR. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric patients with fever and neutropenia. Pediatr. Infect. Dis. J. 2001; 20: 362-9.
19. Hughes WT, Armstrong D, Bodey GP et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. 2002; 34: 730-51.
20. Biron P, Fuhrmann C, Cure H et al. Cefepime vs imipenem-cilastatin as empirical montherapy in 400 febrile patients with short duration neutropenia. J. Antimicrob. Chemother. 1998; 42: 511-18.